Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216586 · ClinicalTrials.gov registry record · Phase 4
Zynrelef Versus Adductor Canal Block
A Phase 4 study, sponsored by University of Miami.
- Not yet
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT07216586: Clinical Trial Phase 4 study, sponsored by University of Miami.
NCT07216586 is a Phase 4 study that has not yet begun recruiting, run by University of Miami. The registered enrollment target is 120 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216586, a Phase 4 study, has not yet begun recruiting, sponsored by University of Miami.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
To compare postoperative MME consumption 72 hours after TKA in patients receiving intraoperative periarticular HTX-011 (Zynrelef) instillation versus adductor canal block.
Primary Outcome
Mean cumulative milligram morphine equivalents (MME) administered at 4, 8, 12, 16, 20, 24, 48, and 72 hours following total knee arthroplasty (TKA). Values will be compared between patients receiving Zynrelef and those receiving adductor canal block (ACB)
Interventions
- DRUG Ropivacaine 0.5% Injectable Solution
- DRUG ZYNRELEF 400Mg-12Mg Extended-Release Solution
- PROCEDURE Ultrasound-Guided Adductor Canal Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2027-01 |
| Est. Completion | 2028-01 |
| Phase | Phase 4 |
What is known before NCT07216586 opens enrollment
NCT07216586 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which Ropivacaine 0.5% Injectable Solution is the first listed.
NCT07216586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07216586 about?
NCT07216586 is a clinical study titled "Zynrelef Versus Adductor Canal Block". To compare postoperative MME consumption 72 hours after TKA in patients receiving intraoperative periarticular HTX-011 (Zynrelef) instillation versus adductor canal block.
What is the current status of trial NCT07216586?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2027-01. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07216586?
The interventions under investigation include: Ropivacaine 0.5% Injectable Solution (DRUG), ZYNRELEF 400Mg-12Mg Extended-Release Solution (DRUG), Ultrasound-Guided Adductor Canal Block (PROCEDURE).
Who is sponsoring clinical trial NCT07216586?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07216586's enrollment target sits among peer trials
120 673rd of 2000 higher than 1,289 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia